Aoki, Yoichi http://orcid.org/0000-0003-3545-8639
Ochiai, Kazunori http://orcid.org/0000-0001-5467-1756
Lim, Soyi
Aoki, Daisuke
Kamiura, Shoji
Lin, Hao
Katsumata, Noriyuki
Cha, Soon-Do
Kim, Jae-Hoon
Kim, Byoung-Gie
Hirashima, Yasuyuki
Fujiwara, Keiichi
Kim, Young-Tak
Kim, Seok Mo
Chung, Hyun Hoon
Chang, Ting-Chang
Kamura, Toshiharu
Takizawa, Ken
Takeuchi, Masahiro
Kang, Soon-Beom
Funding for this research was provided by:
Taiho Pharmaceutical Co., Ltd.
Article History
Received: 26 December 2017
Revised: 18 June 2018
Accepted: 10 July 2018
First Online: 3 August 2018
Ethics approval and consent to participate
: This study was conducted in compliance with Good Clinical Practice, the Declaration of Helsinki, and each country’s regulations governing the conduct of clinical trials. The study protocol was approved by the institutional review board at each site prior to the initiation of the study. All patients provided written informed consent before enrolment.
: This work was supported by Taiho Pharmaceutical Co., Ltd.
: Y.A. has received research funding from Taiho. K.O. has served as a consultant for Taiho and Zeria. S.L. has received travel expense from Taiho. D.A. has received honoraria and research funding from Taiho. N.K. has received honoraria from Taiho, Sawai, Pfizer, Kyowa Hakko Kirin, Ono, Eisai, Takeda, Chugai, Nippon Kayaku, GlaxoSmithKline, Shionogi, Daiichi Sankyo, Yakult, Astellas, and Mochida. Y.H. has received honoraria from Taiho. K.F. has received honoraria from Kyowa Hakko Kirin, Zeria, Nippon Kayaku, Chugai, Eisai, Taiho, Yakult Honsha, Janssen Oncology, Daiichi Sankyo, Novartis, Eli Lilly Japan, Asahi Kasei, and Ono; has served as a consultant for Chugai, AstraZeneca, MSD, Pfizer, Taiho, and Eisai; and has received research funding from Eisai, GlaxoSmithKline, Taiho, Pfizer, Kaken, Chugai, Shionogi, Immunogen, Oncotherapeutics, AstraZeneca, Eli Lilly, Zeria, Ono, and MSD. M.T. has served as a consultant for AstraZeneca, Hisamitsu, AbbVie, Kyorin, Sanofi, Kowa, Taiho, Takeda, and Mitsubishi Tanabe. The remaining authors declare no competing interests.
: This study was conducted in compliance with Good Clinical Practice, the Declaration of Helsinki, and each country’s regulations governing the conduct of clinical trials. The study protocol was approved by the institutional review board at each site prior to the initiation of the study. All patients provided written informed consent before enrolment.